A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus
β Scribed by Vibeke Strand
- Book ID
- 107553951
- Publisher
- Springer
- Year
- 2007
- Tongue
- English
- Weight
- 187 KB
- Volume
- 9
- Category
- Article
- ISSN
- 1523-3774
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Objective B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in p
## Abstract ## Objective In a crossβsectional study, we previously identified 2 potentially modifiable risk factors for adverse outcomes in systemic lupus erythematosus (SLE): selfβefficacy and social support. The goal of this study was to evaluate in a randomized controlled trial a theoryβbased i